NCT02979522 2025-11-10
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Takeda
Phase 1/2 Active not recruiting
Clinical Trials
5 trialsNCT01492088 2024-05-30
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Takeda
Phase 1/2 Completed
NCT02572167 2022-11-08
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Seagen Inc.
Phase 1/2 Completed
NCT01874054 2019-02-12
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Seagen Inc.
Phase 1/2 Completed
NCT00051597 2011-10-12
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
Seagen Inc.
Phase 1/2 Completed